InPen is an FDA-cleared smart insulin pen on the market for people on multiple daily injections (MDI). This system now provides real-time glucose readings alongside insulin dose information. Rather than switching between apps, users have the ability to see all their information in real-time, in one view.
The integration of real-time CGM data into the smart insulin pen app is a result of the addition of Companion Medical’s InPen to the Medtronic portfolio, as of September 2020.
Sean Salmon, executive vice president and president of the diabetes business at Medtronic, said: “We’re strongly committed to delivering solutions that make life easier for people living with diabetes. We’re pleased to build on the success of InPen with added real-time glucose data which provides a complete picture for users as they look to give themselves the right dose of insulin at the right time. Our successful integration of these devices in just two months following the close of our Companion Medical acquisition is a testament to the close collaboration of our employees and strong passion to serve our customers with better solutions to manage their diabetes.”
The InPen app will continue to display information from other currently compatible CGM systems on a three-hour delay.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.